sur TRANSGENE (EPA:TNG)
Transgene to Present VacDesignR® Tool at ESMO AI 2025
Transgene, a biotech company focused on designing virus-based cancer therapies, announced it will showcase its VacDesignR® computational tool at the ESMO AI & Digital Oncology 2025 conference in Berlin. This tool improves the design and efficiency of recombinant Modified Vaccinia Ankara (MVA)-based vectors. It supports the production of individualized neoantigen therapeutic vaccines (INTV), currently under clinical trial.
VacDesignR® optimizes recombinant plasmid architecture for MVA vectors, enhancing production reliability. Future updates will integrate AI components to boost performance and scalability, aligning with Transgene's strategic goals. The tool aids in developing individualized vaccines such as TG4050 for HPV-negative head and neck cancers.
The presentation includes a poster entitled “VacDesignR®: a tool for optimizing recombinant poxvirus vaccine production,” at the ESMO-AI conference on November 12, 2025.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TRANSGENE